PE20000356A1 - FORMA VI DE 5,6-DICLORO-2-(ISOPROPILAMINO)-1-(ß-L-RIBOFURANOSIL)-1H-BENCIMIDAZOL - Google Patents

FORMA VI DE 5,6-DICLORO-2-(ISOPROPILAMINO)-1-(ß-L-RIBOFURANOSIL)-1H-BENCIMIDAZOL

Info

Publication number
PE20000356A1
PE20000356A1 PE1999000264A PE00026499A PE20000356A1 PE 20000356 A1 PE20000356 A1 PE 20000356A1 PE 1999000264 A PE1999000264 A PE 1999000264A PE 00026499 A PE00026499 A PE 00026499A PE 20000356 A1 PE20000356 A1 PE 20000356A1
Authority
PE
Peru
Prior art keywords
ribofuranosil
isopropylamine
dichloro
benzimidazole
refers
Prior art date
Application number
PE1999000264A
Other languages
English (en)
Inventor
Barry Howard Carter
Lian-Feng Huang
Anne Hodgson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20000356A1 publication Critical patent/PE20000356A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA VI DEL COMPUESTO ANTIVIRAL 5,6-DICLORO-2-(ISOPROPILAMINO)-1-(ß-L-RIBOFURANOSIL)-1H-BENCIMIDAZOL CONOCIDO COMO 1263 W94, CARACTERIZADA POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE LA FORMA VI Y LA FORMA AMORFA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE LA CRISTALIZACION DE 5,6-DICLORO-2-(ISOPROPILAMINO)-1-ß-L-RIBOFURANOSIL-1H-BENCIMIDAZOL EN SOLUCION ACUOSA. EL COMPUESTO I PUEDE SER UTIL PARA EL TRATAMIENTO DE INFECCIONES VIRALES CAUSADAS POR EL VIRUS DEL HERPES
PE1999000264A 1998-04-07 1999-04-05 FORMA VI DE 5,6-DICLORO-2-(ISOPROPILAMINO)-1-(ß-L-RIBOFURANOSIL)-1H-BENCIMIDAZOL PE20000356A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9807355.4A GB9807355D0 (en) 1998-04-07 1998-04-07 Antiviral compound

Publications (1)

Publication Number Publication Date
PE20000356A1 true PE20000356A1 (es) 2000-04-26

Family

ID=10829933

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000264A PE20000356A1 (es) 1998-04-07 1999-04-05 FORMA VI DE 5,6-DICLORO-2-(ISOPROPILAMINO)-1-(ß-L-RIBOFURANOSIL)-1H-BENCIMIDAZOL

Country Status (40)

Country Link
US (1) US6482939B1 (es)
EP (1) EP1070078B1 (es)
JP (1) JP2002510702A (es)
KR (1) KR100573635B1 (es)
CN (1) CN1222534C (es)
AP (1) AP2000001946A0 (es)
AR (1) AR014973A1 (es)
AT (1) ATE231517T1 (es)
AU (1) AU753527B2 (es)
BG (1) BG104909A (es)
BR (2) BR9909471A (es)
CA (1) CA2327495C (es)
CO (1) CO5011057A1 (es)
DE (1) DE69905025T2 (es)
DK (1) DK1070078T3 (es)
EA (1) EA002953B1 (es)
EE (1) EE04121B1 (es)
EG (1) EG24597A (es)
ES (1) ES2191429T3 (es)
GB (1) GB9807355D0 (es)
GE (1) GEP20022840B (es)
HK (1) HK1032060A1 (es)
HR (1) HRP20000670B1 (es)
HU (1) HUP0101549A3 (es)
ID (1) ID26573A (es)
IL (2) IL138559A0 (es)
IS (1) IS5634A (es)
MA (1) MA26617A1 (es)
NO (1) NO316896B1 (es)
NZ (1) NZ507012A (es)
OA (1) OA11534A (es)
PE (1) PE20000356A1 (es)
PL (1) PL194752B1 (es)
PT (1) PT1070078E (es)
SI (1) SI1070078T1 (es)
SK (1) SK283735B6 (es)
TR (1) TR200002847T2 (es)
WO (1) WO1999051617A2 (es)
YU (1) YU58600A (es)
ZA (1) ZA200005197B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
US20110008463A1 (en) * 2008-03-12 2011-01-13 Jan Pieter Hendrik Bosselaers Combinations of hydroxypyrion compounds and silver compounds
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
US8541391B2 (en) * 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8546344B2 (en) 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
WO2023105483A1 (en) * 2021-12-10 2023-06-15 Assembly Biosciences, Inc. Crystalline forms of a 5-aminopyrazole compound useful for treating hbv
WO2024081308A1 (en) 2022-10-12 2024-04-18 Takeda Pharmaceutical Company Limited Method of preparing maribavir

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399987A (en) 1965-08-02 1968-09-03 United States Borax Chem 2-alkylaminobenzimidazoles as herbicides
CH443777A (de) 1965-08-06 1968-02-15 Agripat Sa Verfahren zum Schützen textiler Keratinfasern vor Insektenfrass und Mittel zur Durchführung dieses Verfahrens
US3655901A (en) 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
AU5447094A (en) 1992-10-21 1994-05-09 Regents Of The University Of Michigan, The Polysubstituted benzimidazoles as antiviral agents
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
GB2319961A (en) 1996-12-07 1998-06-10 Glaxo Group Ltd Pharmaceutical composition for treatment of restenosis
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound

Also Published As

Publication number Publication date
PT1070078E (pt) 2003-06-30
US6482939B1 (en) 2002-11-19
ZA200005197B (en) 2001-09-27
IS5634A (is) 2000-09-22
AU753527B2 (en) 2002-10-17
CO5011057A1 (es) 2001-02-28
SI1070078T1 (en) 2003-08-31
DE69905025T2 (de) 2003-10-16
EP1070078A2 (en) 2001-01-24
GEP20022840B (en) 2002-11-25
CA2327495A1 (en) 1999-10-14
JP2002510702A (ja) 2002-04-09
PL194752B1 (pl) 2007-07-31
CA2327495C (en) 2009-01-20
CN1304413A (zh) 2001-07-18
DK1070078T3 (da) 2003-05-19
WO1999051617A2 (en) 1999-10-14
EP1070078B1 (en) 2003-01-22
BR9909471A (pt) 2000-12-19
HK1032060A1 (en) 2001-07-06
BG104909A (bg) 2001-06-29
HUP0101549A3 (en) 2003-07-28
SK14822000A3 (sk) 2001-07-10
EE200000585A (et) 2002-04-15
EA002953B1 (ru) 2002-12-26
AR014973A1 (es) 2001-04-11
KR100573635B1 (ko) 2006-04-26
NZ507012A (en) 2003-06-30
MA26617A1 (fr) 2004-12-20
HRP20000670B1 (en) 2004-04-30
IL138559A (en) 2006-12-31
EE04121B1 (et) 2003-08-15
IL138559A0 (en) 2001-10-31
BRPI9909471B8 (pt) 2021-05-25
YU58600A (sh) 2003-04-30
ES2191429T3 (es) 2003-09-01
SK283735B6 (sk) 2003-12-02
OA11534A (en) 2004-05-06
NO20005003D0 (no) 2000-10-04
ID26573A (id) 2001-01-18
EA200000909A1 (ru) 2001-06-25
PL343712A1 (en) 2001-08-27
WO1999051617A3 (en) 1999-12-09
NO20005003L (no) 2000-12-06
BRPI9909471B1 (pt) 2018-11-21
CN1222534C (zh) 2005-10-12
TR200002847T2 (tr) 2001-01-22
AU3703899A (en) 1999-10-25
DE69905025D1 (de) 2003-02-27
EG24597A (en) 2009-12-14
GB9807355D0 (en) 1998-06-03
HRP20000670A2 (en) 2000-12-31
HUP0101549A2 (hu) 2001-10-28
AP2000001946A0 (en) 2000-12-31
NO316896B1 (no) 2004-06-14
ATE231517T1 (de) 2003-02-15
KR20010074473A (ko) 2001-08-04

Similar Documents

Publication Publication Date Title
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
ES2113881T3 (es) Derivados y analogos de acido 2-desoxi-2,3-didehidro-n-acetil neuraminico y su utilizacion como agentes antivirales.
PA8588501A1 (es) Derivados antivirales de nucleósidos
CL2011001906A1 (es) Compuestos derivados de ribosidos de tieno[3,4-d]pirimidin-7-ilo, y fosfatos de ribosidos; compuestos intermediarios; metodos de preparacion; metodo de tratamiento; composicion farmaceutica; y su uso para tratar una infeccion viral causada por un virus hepatitis c o un virus flaviridae.
BR9909474A (pt) Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
BR0011705A (pt) Derivados de purina
ES2191977T3 (es) Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
WO2002062290A3 (en) Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
BRPI0313942C1 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
DOP2006000289A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20000356A1 (es) FORMA VI DE 5,6-DICLORO-2-(ISOPROPILAMINO)-1-(ß-L-RIBOFURANOSIL)-1H-BENCIMIDAZOL
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
ECSP099462A (es) Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c
ECSP10010210A (es) Compuestos nucleósidos antivirales
BRPI0412327A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
ES2059786T3 (es) Composicion blanqueante.
WO2004037784A3 (en) Pyrrolidones with anti-hiv activity
AR025046A1 (es) Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores
AR035064A1 (es) 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos
PE61699A1 (es) Composicion farmaceutica de lamivudina
WO2004043402A3 (en) Modified nucleosides as antiviral agents
WO2008118879A3 (en) Antiviral compositions comprising 2 compounds

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed